# US 2012/0252810 A1 · Fatty acid non-flushing niacin derivatives and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252810 A1
- Document ID: US20120252810A1
- Status: Published application
- Kind: A1
- Application number: 13/439,168
- Filed: 2012-04-04
- Published: 2012-10-04
- Earliest claimed: 2011-04-04
- Assignees: Catabasis Pharmaceuticals, Inc.
- Inventors: Chi B. Vu; Jean E. Bemis; Michael R. Jirousek; Jill C. Milne; Amal Ting
- Web page: https://patentgrep.com/patent/US20120252810A1

## CPC

- C07D 213/56: Amides
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 419/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to fatty non-flushing acid niacin derivatives; compositions comprising an effective amount of a fatty acid non-flushing niacin derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid non-flushing niacin derivative.

## Claims

### Claim 1

A molecular conjugate comprising a non-flushing niacin and a fatty acid selected from lipoic acid, omega-3 fatty acids or fatty acids metabolized in vivo into omega-3 fatty acids.

### Claim 2

A compound of Formula I:
or a pharmaceutically acceptable salt, enantiomer or stereoisomer thereof;
wherein
Each R1 and R2 is independently hydrogen, deuterium, —C1-C4 alkyl, -halogen, —OH, —C(O)C1-C4 alkyl, —O-aryl, —O-benzyl, —OC(O)C1-C4 alkyl, —C1-C3 alkene, —C1-C3 alkyne, —C(O)C1-C4 alkyl, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —SH, —S(C1-C3 alkyl), —S(O)C1-C3 alkyl, or —S(O)2C1-C3 alkyl;
R5 is independently selected from the group consisting of H, -D, —Cl, —F, —CN, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —C(O)H, —C(O)C1-C3 alkyl, —C(O)OC1-C3 alkyl, —C(O)NH2, —C(O)NH(C1-C3 alkyl), —C(O)N(C1-C3 alkyl)2, —C1-C6 alkyl, —O—C1-C3 alkyl, —S(O)C1-C3 alkyl, —S(O)2C1-C3 alkyl, an aryl, a cycloalkyl, a heterocycle and
R3 is independently H or C1-C6 alkyl, or both R3 groups, when taken together with the nitrogen to which they are attached, can form
wherein f1 is 1, 2, 3 or 4; and f2 is 1, 2 or 3;
W1 and W2 are each independently null, O, S, NH, NR, or W1 and W2 can be taken together can form an imidazolidine or piperazine group, with the proviso that W1 and W2 can not be O simultaneously;
each a, b, c, and d is independently —H, -D, —CH3, —OCH3, —OCH2CH3, —C(O)OR, —O—Z, or benzyl, or two of a, b, c, and d can be taken together, along with the single carbon to which they are bound, to form a cycloalkyl or heterocycle;
each n, o, p, and q is independently 0, 1 or 2;
each L is independently —O—, —S—, —S(O)—, —S(O)2—, —S—S—, —(C1-C6alkyl)-, —(C3-C6cycloalkyl)-, a heterocycle, a heteroaryl,
wherein the representation of L is not limited directionally left to right as is depicted, rather either the left side or the right side of L can be bound to the W1 side of the compound of Formula I;
R6 is independently —H, -D, —C1-C4 alkyl, -halogen, cyano, oxo, thiooxo, —OH, —C(O)C1-C4 alkyl, —O-aryl, —O-benzyl, —OC(O)C1-C4 alkyl, —C1-C3 alkene, —C1-C3 alkyne, —C(O)C1-C4 alkyl, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —SH, —S(C1-C3 alkyl), —S(O)C1-C3 alkyl, or —S(O)2C1-C3 alkyl;
each g is independently 2, 3 or 4;
each h is independently 1, 2, 3 or 4;
m is 0, 1, 2, 3, 4 or 5; if m is more than 1, then L can be the same or different;
m1 is 0, 1, 2 or 3;
k is 0, 1, 2, or 3;
z is 1, 2, or 3;
each R4 independently e, H or straight or branched C1-C10 alkyl which can be optionally substituted with OH, NH2, CO2R, CONH2, phenyl, C6H4OH, imidazole or arginine;
each e is independently H or any one of the side chains of the naturally occurring amino acids;
each Z is independently —H, or
with the proviso that there is at least one
in the compound;
each r is independently 2, 3, or 7;
each s is independently 3, 5, or 6;
each t is independently 0 or 1;
each v is independently 1, 2, or 6;
each R is independently —H, —C1-C3 alkyl, or straight or branched C1-C4 alkyl optionally substituted with OH, or halogen;
provided that
when m, n, o, p, and q are each 0, W1 and W2 are each null, and Z is
then t must be 0; and
when m, n, o, p, and q are each 0, and W1 and W2 are each null, then Z must not be

### Claim 3

A compound of the Formula II:
or a pharmaceutically acceptable salt, enantiomer or stereoisomer thereof;
wherein
each R1 and R2 is independently hydrogen, deuterium, —C1-C4 alkyl, -halogen, —OH, —C(O)C1-C4 alkyl, —O-aryl, —O-benzyl, —OC(O)C1-C4 alkyl, —C1-C3 alkene, —C1-C3 alkyne, —C(O)C1-C4 alkyl, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —SH, —S(C1-C3 alkyl), —S(O)C1-C3 alkyl, —S(O)2C1-C3 alkyl;
R3 is independently H or C1-C6 alkyl, or both R3 groups, when taken together with the nitrogen to which they are attached, can form
wherein f1 is 1, 2, 3 or 4;
W1 and W2 are each independently null, O, S, NH, NR, or W1 and W2 can be taken together can form an imidazolidine or piperazine group, with the proviso that W1 and W2 can not be O simultaneously;
each a, b, c, and d is independently —H, -D, —CH3, —OCH3, —OCH2CH3, —C(O)OR, —O—Z, or benzyl, or two of a, b, c, and d can be taken together, along with the single carbon to which they are bound, to form a cycloalkyl or heterocycle;
each n, o, p, and q is independently 0, 1 or 2;
each L is independently-O—, —S—, —S(O)—, —S(O)2—, —S—S—, —(C1-C6alkyl)-, —(C3-C6cycloalkyl)-, a heterocycle, a heteroaryl,
wherein the representation of L is not limited directionally left to right as is depicted, rather either the left side or the right side of L can be bound to the W1 side of the compound of Formula II;
R6 is independently —H, -D, —C1-C4 alkyl, -halogen, cyano, oxo, thiooxo, —OH, —C(O)C1-C4 alkyl, —O-aryl, —O-benzyl, —OC(O)C1-C4 alkyl, —C1-C3 alkene, —C1-C3 alkyne, —C(O)C1-C4 alkyl, —NH2, —NH(C1-C3 alkyl), —N(C1-C3 alkyl)2, —NH(C(O)C1-C3 alkyl), —N(C(O)C1-C3 alkyl)2, —SH, —S(C1-C3 alkyl), —S(O)C1-C3 alkyl, or —S(O)2C1-C3 alkyl;
each g is independently 2, 3 or 4;
each h is independently 1, 2, 3 or 4;
m is 0, 1, 2, 3, 4 or 5; if m is more than 1, then L can be the same or different;
m1 is 0, 1, 2 or 3;
k is 0, 1, 2, or 3;
z is 1, 2, or 3;
each R4 independently e, H or straight or branched C1-C10 alkyl which can be optionally substituted with OH, NH2, CO2R, CONH2, phenyl, C6H4OH, imidazole or arginine;
each e is independently H or any one of the side chains of the naturally occurring amino acids;
each Z is independently —H, or
with the proviso that there is at least one
in the compound;
each r is independently 2, 3, or 7;
each s is independently 3, 5, or 6;
each t is independently 0 or 1;
each v is independently 1, 2, or 6;
each R is independently —H, —C1-C3 alkyl, or straight or branched C1-C4 alkyl optionally substituted with OH, or halogen;
provided that
when m, n, o, p, and q are each 0, W1 and W2 are each null, and Z is
then t must be 0; and
when m, n, o, p, and q are each 0, and W1 and W2 are each null, then Z must not be

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 1)

A method for treating a metabolic disease, the method comprising administering to a patient in need thereof an effective amount of a molecular conjugate of claim 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the metabolic disease is selected from hypertriglyceridemia, hypercholesterolemia, fatty liver disease, nonalcoholic steatohepatitis (NASH), atherosclerosis, coronary heart disease, Type 2 diabetes, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, metabolic syndrome, or cardiovascular disease.

### Claim 7 (depends on 2)

A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

### Claim 8 (depends on 2)

A method for treating a metabolic disease, the method comprising administering to a patient in need thereof an effective amount of a molecular conjugate of claim 2.

### Claim 9 (depends on 8)

The method of claim 8, wherein the metabolic disease is selected from hypertriglyceridemia, hypercholesterolemia, fatty liver disease, nonalcoholic steatohepatitis (NASH), atherosclerosis, coronary heart disease, Type 2 diabetes, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, metabolic syndrome, or cardiovascular disease.

### Claim 10 (depends on 3)

A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 3)

A method for treating a metabolic disease, the method comprising administering to a patient in need thereof an effective amount of a molecular conjugate of claim 3.

### Claim 12 (depends on 11)

The method of claim 11, wherein the metabolic disease is selected from hypertriglyceridemia, hypercholesterolemia, fatty liver disease, nonalcoholic steatohepatitis (NASH), atherosclerosis, coronary heart disease, Type 2 diabetes, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, metabolic syndrome, or cardiovascular disease.
